KRAS and colorectal cancer: In analyses stratified for molecular subtypes, MIC A/B was associated with a lower risk of KRAS-mutated colorectal cancer (OR: 0.66, 95% CI 0.47–0.93), no proteins were associated with the risk of BRAF-mutated or KRAS-BRAF-wild type colorectal cancer.